Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs, flunitrazepam and haloperidol. Flunitrazepam is a potent benzodiazepine with hypnotic, sedative, anxiolytic, muscle relaxant, and anticonvulsant properties. It acts primarily by enhancing the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. Haloperidol is a typical antipsychotic (neuroleptic) that works mainly as an antagonist at dopamine D2 receptors in the brain. The combination has been studied for rapid control of acute agitation or aggressive behavior in psychiatric emergencies; both agents exhibit antiaggressive activity when administered intramuscularly to acutely psychotic patients[1][3][5]. Flunitrazepam provides rapid onset sedation while haloperidol offers sustained antipsychotic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flunitrazepam + haloperidol.